enGene Therapeutics Income Statement

Financials in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 31, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021
Selling, General & Admin	40.39	28.69	23.98	9.6	3.96	3.41
Research & Development	96.26	94.48	38.32	16.46	15.47	12.46
Operating Expenses	136.65	123.17	62.3	26.06	19.43	15.87
Operating Income	-136.65	-123.17	-62.3	-26.06	-19.43	-15.87
Interest Expense	-3.07	-2.99	-2.8	-4.95	-1.42	-5.02
Interest & Investment Income	9.78	9.43	10.41	1.12	0.13	0.03
Currency Exchange Gain (Loss)	-0.43	-0.57	-0.11	-0.13	-0.7	-0.1
Other Non Operating Income (Expenses)	-	-	-	-10.57	-3.02	-4.2
EBT Excluding Unusual Items	-130.37	-117.3	-54.8	-40.6	-24.44	-25.17
Other Unusual Items	-0.49	-	-0.37	-59.3	-	1.73
Pretax Income	-130.86	-117.3	-55.16	-99.9	-24.44	-23.44
Income Tax Expense	-0.5	-	-0.02	0.02	0.02	-
Net Income	-130.36	-117.3	-55.14	-99.92	-24.46	-23.44
Preferred Dividends & Other Adjustments	-	-	-	4.82	4.56	-1.19
Net Income to Common	-130.36	-117.3	-55.14	-104.74	-29.02	-22.25
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	65	51	38	1	1	4
Shares Outstanding (Diluted)	65	51	38	1	1	4
Shares Change	30.65%	35.30%	5355.08%	5.72%	-81.61%	28.93%
EPS (Basic)	-2.02	-2.29	-1.46	-151.22	-44.30	-6.25
EPS (Diluted)	-2.02	-2.29	-1.46	-151.22	-44.30	-6.25
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 31, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021
Free Cash Flow	-104	-100.72	-49.21	-25.06	-17.75	-16.23
Free Cash Flow Per Share	-1.61	-1.97	-1.30	-36.18	-27.09	-4.56
EBITDA	-135.93	-122.66	-61.97	-25.89	-19.19	-15.6
D&A For EBITDA	0.72	0.51	0.32	0.18	0.24	0.27
EBIT	-136.65	-123.17	-62.3	-26.06	-19.43	-15.87

SEC Filings: 10-K · 10-Q